By analyzing the potential value of HLA-DMB in the diagnosis and treatment of endometrial cancer, we found that it can improve patient survival rates, effectively reducing overall medical costs and providing long-term economic benefits. This evidence concerns the gene HLA-DMB and endometrial cancer.